CN100367959C - Medicine contg. irbesartan - Google Patents
Medicine contg. irbesartan Download PDFInfo
- Publication number
- CN100367959C CN100367959C CNB2006101120699A CN200610112069A CN100367959C CN 100367959 C CN100367959 C CN 100367959C CN B2006101120699 A CNB2006101120699 A CN B2006101120699A CN 200610112069 A CN200610112069 A CN 200610112069A CN 100367959 C CN100367959 C CN 100367959C
- Authority
- CN
- China
- Prior art keywords
- compositions
- medicine
- chinese medicine
- irbesartan
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A synergistic medicine contains irbesartan and the extracts of Chinese-medicine and its application in preparing the medicines for treating hypertension are disclosed.
Description
Technical field
The invention belongs to a kind of medicine, a kind ofly specifically be used for the treatment of the hypertensive compositions that contains Irb.
Background technology
Hypertension is common clinical, frequently-occurring disease.A large amount of research is verified, and hypertension is the most important risk factor of cardiovascular and cerebrovascular disease.The whole nation is three hypertension census results show, nineteen fifty-nine the hypertension prevalence of being grown up more than 15 years old be 7.73% for 5.11%:1979; Rose to 11.8% in 1991, and be ascendant trend year by year.At present, there are hyperpietic 9,000 ten thousand people in the whole nation, increase 3,000,000 hypertensive patients every year newly, corresponding therewith, annual apoplexy new cases 1,500,000, about 1,000,000 people of person that die from the apoplexy every year, the existing about 500-600 ten thousand of apoplexy number of patients, wherein about 75% has lost work capacity to some extent, and severe disabled person accounts for more than 40%, annual economic loss and the medical expense that causes thus is quite surprising, brought serious social concern and heavy financial burden to country.So doing a good job of it with prevention, control hypertension is the cardiovascular and cerebrovascular disease preventing and controlling of breach, has been the task of top priority.
At present, though doctor trained in Western medicine has obtained certain progress to hypertensive research, new medicine comes out, and brings new hope to controlling blood pressure, and the most toxic side effect of hypotensor is often taken for a long time and brought many iatrogenic diseases to the patient, loses more than gain.The period in a medicine blood pressure drops, blood pressure easily bounces after the drug withdrawal, and effect is difficult to lasting.Though blood pressure descends sometimes, clinical symptoms is not removed, and what have increases the weight of on the contrary, and the labour force can not recover.And new depressor costs an arm and a leg mostly, and general patient is difficult to bear, and is not inconsistent inconvenient penetration and promotion with China's national situation.In the face of new problem, Chinese medicine has been cooked a large amount of work in recent years preventing and treating aspect the hypertension, obtained gratifying achievement, demonstrated certain advantage, but clinical practice is based on traditional decoction, though curative effect is preferably arranged, so time-consuming because of decocting, the waste medical material, the dosage form transmutability is big, be difficult to problems such as large tracts of land popularization, make the patient be difficult to adhere to for a long time, thereby influenced the normal performance of curative effect, do not reach the intended purposes of control.Filtered out a collection of single medicinal material, though take easy, but because of kind, limited amount, simultaneously, also simple because of the single practical application, can not embody the tcm characteristic that dialectical opinion is controlled, exist the limitation identical too with Western medicine, though be that blood pressure had decline after many patients took medicine, clinical symptoms does not subtract, the irreclaimable problem of labour force.
No matter the Chinese medicine hypertension is controlled in dialectical opinion, and single medicinal material is used and the zoopery aspect proves that all hypotensive effect is definite, and has and have no side effect, and curative effect is lasting, is difficult for advantages such as recurrence.But, be difficult to grasp unfavorable promoting the use because dialectical pattern of syndrome is unfixing.Some single medicine of hiding is effective in cure, but is difficult to solve simultaneous phenomenon, and the single drug effect a little less than, escalated dose problem such as easily have side effects again.
The present invention attempts Chinese medicine and Western medicine are combined, and with the problem of avoiding existing separately, and improves hypertensive therapeutic effect, promptly produces synergism.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of Irb and a kind of Chinese medicine extract, wherein prepares on the basis of the Chinese medicine extract of said composition according to the 6th page of specific embodiment of Chinese patent CN1150930C description, and is as follows:
Take by weighing 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, add 9 times distilled water, after water logging half an hour, heating extraction 2 times is boiled 30 minutes after-filtration at every turn, and residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the hypertensive medicine of preparation treatment.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong antihypertensive function, i.e. hypotensive activity.
The following medicine of respectively organizing is awarded spontaneous hypertensive rat (SHR) and mouthful raised administration 15 days, and the result all can obviously reduce the blood pressure of SHR.Experimental result sees the following form.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 1.02g/kg body weight as indicated above
3 irbesartan groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight irbesartan+extractum 1.02g/kg body weight mentioned above is irritated stomach.
| Group (n=10) | Blood pressure mmHg | ||
| 0 day | 5 days | 15 days | |
| Group 1 | ?139.3±5.6 | ?165.5±5.1 | ?177.8±6.7 |
| Group 2 | ?145.5±3.2 | ?136.8±2.9 | ?138.8±3.8 |
| Group 3 | ?145.1±3.2 | ?126.1±4.5 | ?126.8±3.8 |
| Group 4 | ?149.8±2.6 | ?114.5±3.8 | ?118.2±5.1 |
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, irbesartan group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and irbesartan group.Show that there are cooperative effect in irbesartan and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio irbesartan and described Chinese medicine extract at 1: 102.
Can produce the capsule that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Pulvis Talci 5.0
Wherein compositions is made up of with weight ratio irbesartan and described Chinese medicine extract at 1: 102.
Claims (2)
1. treat hypertensive compositions for one kind, it was made up of Irb and Chinese medicine extract in 1: 102 by weight, wherein Chinese medicine extract is obtained by following method: take by weighing by weight 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, the distilled water that adds 9 times, after water logging half an hour, heating extraction 2 times is boiled 30 minutes after-filtration at every turn, residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
2. the purposes of compositions as claimed in claim 1 in the hypertensive medicine of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101120699A CN100367959C (en) | 2006-08-29 | 2006-08-29 | Medicine contg. irbesartan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101120699A CN100367959C (en) | 2006-08-29 | 2006-08-29 | Medicine contg. irbesartan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1911429A CN1911429A (en) | 2007-02-14 |
| CN100367959C true CN100367959C (en) | 2008-02-13 |
Family
ID=37720593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101120699A Expired - Fee Related CN100367959C (en) | 2006-08-29 | 2006-08-29 | Medicine contg. irbesartan |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100367959C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708326B (en) * | 2009-12-21 | 2011-06-22 | 罗丹晓 | Medicine containing nifedipine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1366986A (en) * | 2001-10-26 | 2002-09-04 | 中国中医研究院中药研究所 | Cinnamon twig decoction extract for preventing and curing hypertension |
| CN1610548A (en) * | 2001-10-26 | 2005-04-27 | 法商沙诺费-辛芷拉保公司 | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension |
-
2006
- 2006-08-29 CN CNB2006101120699A patent/CN100367959C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1366986A (en) * | 2001-10-26 | 2002-09-04 | 中国中医研究院中药研究所 | Cinnamon twig decoction extract for preventing and curing hypertension |
| CN1610548A (en) * | 2001-10-26 | 2005-04-27 | 法商沙诺费-辛芷拉保公司 | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1911429A (en) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100381163C (en) | Medicine comprising rilmenidine | |
| CN101732688B (en) | Amlodipine-containing medicament | |
| CN101773657B (en) | Medicine containing sodium nitroprusside | |
| CN100367959C (en) | Medicine contg. irbesartan | |
| CN100367956C (en) | Medicine for treating hypertension | |
| CN101732689B (en) | Minoxidil-containing medicament | |
| CN101708326B (en) | Medicine containing nifedipine | |
| CN101708325B (en) | Medicine containing propranolol | |
| CN105250954B (en) | A kind of Chinese medicine for treating IBS and preparation method thereof | |
| CN104306662A (en) | Traditional Chinese medicine composition for treating neurasthenia and preparation method thereof | |
| CN101732686B (en) | Metoprolol-containing medicament | |
| CN101810839B (en) | Diltiazem-containing medicine | |
| CN101810840B (en) | Medicament containing terazosin | |
| CN101732687B (en) | Methyldopa-containing medicament | |
| CN101502635B (en) | Medicament composition containing Reserpine | |
| CN101773658B (en) | Medicine containing indapamide | |
| CN101439178B (en) | Medicament containing Urapidil | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN102552711B (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN103638149A (en) | Traditional Chinese medicine composition for treating rectal cancer | |
| CN102430073A (en) | Medicinal composition for treating peptic ulcer | |
| CN107158268A (en) | It is a kind of to treat Chinese medicine composition of hypertension and its preparation method and application | |
| CN101773545A (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN1634541A (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof | |
| CN104435437A (en) | Traditional Chinese medicine for treating prosopalgia and intercurrent glossopharyngeal neuralgia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Xue Document name: Notification to Pay the Fees |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Xue Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |